filmov
tv
Dr. Goy Discusses Single-Agent Ibrutinib in MCL
Показать описание
OncLive
cancer
oncology
Рекомендации по теме
0:01:25
Dr. Goy Discusses Single-Agent Ibrutinib in MCL
0:01:09
Dr. Goy Discusses Ibrutinib With Venetoclax in MCL
0:01:56
Dr. Goy Discusses Long-Term Follow-Up Results for Ibrutinib in MCL
0:01:06
Dr. Goy on Efficacy With Ibrutinib in MCL
0:01:00
Dr. Goy on Acalabrutinib Versus Ibrutinib in MCL
0:01:20
Dr. Wang Discusses Single-Agent Acalabrutinib in MCL
0:01:25
Dr. Goy Discusses Challenges in Treatment of MCL
0:02:00
Dr. Goy Discusses BTK Inhibitors in MCL
0:01:48
Goy Predicts Strategies for the Future of MCL Treatment
0:19:58
New Agents for Mantle Cell Lymphoma
0:09:02
Efficacy and Future Role of Ibrutinib in CLL and MCL
0:21:42
Update on BTK inhibitors for CLL: Ibrutinib pus the new kids on the block: Are they better?
0:00:54
Dr. Wang on Updated Data With Single-Agent Acalabrutinib in MCL
0:01:06
Dr. Goy on Promising Data With Acalabrutinib in MCL
0:01:33
Dr. Jacobs on the Efficacy of Ibrutinib and Acalabrutinib in Patients With MCL
0:01:34
The success of ibrutinib in treating mantle cell lymphoma (MCL)
0:01:45
Dr. Fakhri on Ibrutinib-Containing Regimens in CLL
0:01:23
Dr. Barrientos Discusses Ibrutinib in Elderly Populations With CLL
0:24:17
Combination of Novel Agents in CLL: Is this the Final Answer?
0:01:35
Dr. Goy on Prognostic Markers in Mantle Cell Lymphoma
0:02:18
The combination of ibrutinib and obinutuzumab in CLL
0:05:44
Acalabrutinib Versus Ibrutinib for CLL
0:02:16
Dr. Ruan Discusses BTK Inhibitors in MCL
0:01:56
Dr. Tam on the Combination of Ibrutinib Plus Venetoclax in Mantle Cell Lymphoma
0:01:25
0:01:09
0:01:56
0:01:06
0:01:00
0:01:20
0:01:25
0:02:00
0:01:48
0:19:58
0:09:02
0:21:42
0:00:54
0:01:06
0:01:33
0:01:34
0:01:45
0:01:23
0:24:17
0:01:35
0:02:18
0:05:44
0:02:16
0:01:56